All In Biotech

BLA 761196 · Adc Therapeutics SA

Zynlonta

Loncastuximab Tesirine-Lpyl · Injection

NovelAccelerated approvalPriority reviewOrphan

CDER novel approval, Apr 23, 2021: To treat certain types of relapsed or refractory large B-cell lymphoma

Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2021

Apr 23, 2021

Approved uses

1

Original approval plus efficacy supplements

Registered trials

35

2 Phase 3, 13 recruiting

FAERS reports

410

308 serious, 146 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 11, 2026.

ZYNLONTA is indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, DLBCL arising from low-grade lymphoma, and high-grade B-cell lymphoma. This indication is approved under accelerated approval based on overall response rate [see Clinical Studies (14.1) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). ZYNLONTA is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, DLBCL arising from low-grade lymphoma, and high-grade B-cell lymphoma. ( 1 ) This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). ( 1 )

Mechanism: Loncastuximab tesirine-lpyl is an antibody-drug conjugate (ADC) targeting CD19. The monoclonal IgG1 kappa antibody component binds to human CD19, a transmembrane protein expressed on the surface of cells of B-lineage origin. The small molecule component is SG3199, a PBD dimer and alkylating agent. Upon binding to CD19, loncastuximab tesirine-lpyl is internalized followed by release of SG3199 via proteolytic cleavage. The released SG3199 binds to the DNA minor groove and forms highly cytotoxic DNA interstrand crosslinks, subsequently inducing cell death. Loncastuximab tesirine-lpyl had...

Therapeutic areas: Hematology and blood cancers

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Apr 23, 2021 Original approval · Type 1 - New Molecular Entity · priority review NovelAccelerated approvalOrphanLabelLetterReview
1 products under this application
  • ZYNLONTA · LONCASTUXIMAB TESIRINE-LPYL 10MG · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Loncastuximab Tesirine" as an intervention, any sponsor and status, largest first.

All 35 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • death69
  • disease progression33
  • rash32
  • pleural effusion24
  • fatigue22
  • photosensitivity reaction21
  • neutropenia18
  • anaemia16
  • thrombocytopenia15
  • covid-1914
  • oedema14
  • off label use14

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20171
20181
20191
202126
202284
202377
202462
202568
202690

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Zynlonta (Loncastuximab Tesirine-Lpyl)

2024 spending

$288K

Beneficiaries

n/a

11 claims

Per beneficiary

n/a

$26,187.08 per unit

View as table
YearSpending
2020$0
2021$0
2022$823,081
2023$674,926
2024$288,058

Part B: Zynlonta (Loncastuximab Tesirine-Lpyl) · HCPCS J9359

2024 spending

$27.3M

Beneficiaries

243

976 claims

Per beneficiary

$112,232

2024 ASP limit $203.48 per unit

View as table
YearSpending
2020$0
2021$0
2022$23,389,056
2023$29,146,424
2024$27,272,265

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 12 on PubMed

Sponsor: Adc Therapeutics SA

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.